Delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema.

ABSTRACT:

Background

Lymphedema is a chronic disease results from impaired flow of the lymphatic system. Therefore, reconstruction of lymphatic system is crucial to treat limb lymphedema. Vascular endothelial growth factor (VEGFC) has been reported to be an important regulator involved in the growth and differentiation of lymphatic endothelial cells; however; the application of exosomes with VEGFC in the treatment of lymphedema has been rarely reported.

Methods

From the membrane-based fusion technology, we constructed engineered exosomes that overexpress CD63-VEGFC fusion protein (CD63-VEGFC/exos). We examined the in vitro effects of CD63-VEGFC/exos on the proliferation, migration, and tube formation of human dermal lymphatic endothelial cells (HDLECs) by MTT assay, migration a

SUBMITTER: Li B 

PROVIDER: S-EPMC7729376 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature